ESPERITE 2,154,000 shares exchanged today. Thank you for your interest in our company (23/02/2015)
ESPERITE (ESP) 2,154,000 shares EXCHANGED TODAY. THE COMPANY publishes this note of appreciation addressed to all the investors who massively increased the volume of transactions at the Euronext stock exchange today.
ESPERITE pioneers first treatment worldwide of Cerebral Palsy using two types of stem cells (23/02/2015)
CryoSave, part of ESPERITE, is the only private cord blood bank sponsoring a GCP clinical trial according to GMP-ATMP international guidelines. CryoSave leads and sponsors a multicentre clinical trial following GCP-ICH standards, for investigation of new treatment of Cerebral Palsy using dual infusion of two types of stem cells derived from umbilical cord blood and cord tissue processed by CryoSave
ESPERITE tackles Autism with revolutionary Genetic test (05/02/2015)
ESPERITE announced today the launch of REALITY, the new-generation genetic predisposition test for autism. REALITY is pivotal for tackling autism because the child can be tested at an early age, even at birth. This allows for early intervention which is the most effective approach to alter how autism develops. REALITY is a risk-free, convenient, affordable and reliable test, with results available in less than 3 weeks. ESPERITE has acquired exclusive worldwide distribution rights (excluding the United
States) for IntegraGen’s autism test, the first of its kind marketed in the United States.
Esperite (ESP) invests in multimillion largest clinical Genetic center and aims for pole position in Europe (04/02/2015)
ESPERITE, the European leader since 2000 in the stem cells life science business, is launching unique new-generation genetic tests. Risk-free, convenient, affordable and accurate tests with results available in a few days. ESPERITE eases its clients the key genetic information to personalize their health-related decisions, fostering a new culture of consumer empowerment towards a proactive approach to health.